Performance of low-cost non-invasive blood markers of liver cirrhosis in adults with chronic hepatitis B infection with and without comorbid alcohol use in Zambia
Résumé
Abstract Background Diagnosis of liver cirrhosis in patients with chronic hepatitis B is challenging given rare use of biopsy. In low and middle-income countries, transient elastography (TE), a recommended non-invasive imaging test for cirrhosis is rarely accessible. We therefore investigated the performance of multiple low-cost and more accessible blood-based liver fibrosis markers in patients with chronic hepatitis B infection in Zambia. As alcohol use complicates the assessment and outcomes of hepatitis B, we also considered alcohol use patterns in our evaluation. Methods We performed a hospital-based cross-sectional study, in Lusaka, Zambia, among consecutive treatment-naive adults with chronic hepatitis B mono-infection (i.e., HIV-negative) presenting to our hospital. The reference test for cirrhosis was TE of >/=9.6 kPa. Low-cost markers were the AST-to-platelet ratio index (APRI) at recommended threshold >2, as well as lower proposed alternative thresholds for Africa, >0.5 and >0.65, AST/ALT ratio and FIB-4 index >3.25. We evaluated the performance of each marker versus TE. In a secondary analysis, we evaluated marker performance in participants with current alcohol use versus lifetime abstinence. Results Among 239 adults with HBV mono-infection analyzed, the mean age was 34.7 years and 53 (22.2%) reported current alcohol use. The prevalence of cirrhosis by TE was 16.3% (95% CI: 11.87-21.63). The area under the receiver operating characteristic curve was 0.83, 0.80, 0.79 and 0.73 for FIB-4, APRI >0.5, APRI >0.65 and APRI >2 respectively. Virtually all indices performed less well in people with current alcohol use. Conclusion These data support the adoption of a lower APRI threshold in Africa, and the use of the FIB-4 index, for diagnosis of cirrhosis among patients with chronic hepatitis B infection. The currently-recommended APRI threshold may exclude people with cirrhosis who need antiviral therapy. Clinicians adopting these markers should screen for alcohol use and consider re-assessment of cirrhosis after alcohol reduction.
Citer ce document
Accès au document
Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter
Statistiques
Consultations : 1
Téléchargements : 0